HU0202282D0 - - Google Patents

Info

Publication number
HU0202282D0
HU0202282D0 HU0202282A HUP0202282A HU0202282D0 HU 0202282 D0 HU0202282 D0 HU 0202282D0 HU 0202282 A HU0202282 A HU 0202282A HU P0202282 A HUP0202282 A HU P0202282A HU 0202282 D0 HU0202282 D0 HU 0202282D0
Authority
HU
Hungary
Application number
HU0202282A
Other languages
Hungarian (hu)
Original Assignee
Laboratoirs Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoirs Servier filed Critical Laboratoirs Servier
Publication of HU0202282D0 publication Critical patent/HU0202282D0/hu
Publication of HUP0202282A2 publication Critical patent/HUP0202282A2/hu
Publication of HUP0202282A3 publication Critical patent/HUP0202282A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0202282A 2001-07-12 2002-07-12 Novel octahydro-2h-pyrido[1,2-a]pyrazine compounds, process for their preparation and pharmaceutical compositions containing them HUP0202282A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0109260A FR2827288B1 (fr) 2001-07-12 2001-07-12 Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number Publication Date
HU0202282D0 true HU0202282D0 (enExample) 2002-09-28
HUP0202282A2 HUP0202282A2 (hu) 2003-03-28
HUP0202282A3 HUP0202282A3 (en) 2003-11-28

Family

ID=8865405

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202282A HUP0202282A3 (en) 2001-07-12 2002-07-12 Novel octahydro-2h-pyrido[1,2-a]pyrazine compounds, process for their preparation and pharmaceutical compositions containing them

Country Status (24)

Country Link
US (1) US6992085B2 (enExample)
EP (1) EP1275647B1 (enExample)
JP (1) JP3950018B2 (enExample)
KR (1) KR100485020B1 (enExample)
CN (1) CN1197863C (enExample)
AR (1) AR036166A1 (enExample)
AT (1) ATE254124T1 (enExample)
AU (1) AU2002300094B2 (enExample)
BR (1) BR0202681A (enExample)
CA (1) CA2394027C (enExample)
DE (1) DE60200089T2 (enExample)
DK (1) DK1275647T3 (enExample)
EA (1) EA005160B1 (enExample)
ES (1) ES2210219T3 (enExample)
FR (1) FR2827288B1 (enExample)
HU (1) HUP0202282A3 (enExample)
MX (1) MXPA02006699A (enExample)
NO (1) NO322966B1 (enExample)
NZ (1) NZ520120A (enExample)
PL (1) PL355034A1 (enExample)
PT (1) PT1275647E (enExample)
SI (1) SI1275647T1 (enExample)
TR (1) TR200302001T4 (enExample)
ZA (1) ZA200205596B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004089410A1 (ja) * 2003-04-03 2006-07-06 協和醗酵工業株式会社 神経因性疼痛の予防及び/または治療剤
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0512567A (pt) * 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
CN103110635A (zh) * 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
RU2442775C2 (ru) * 2005-07-04 2012-02-20 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
WO2007106349A2 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
KR100871691B1 (ko) 2006-10-16 2008-12-05 삼성전자주식회사 병렬 비트 테스트 방법 및 그 방법을 사용하는 반도체메모리 장치
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CA3089498A1 (en) 2018-01-26 2019-08-01 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
GB8518236D0 (en) * 1985-07-19 1985-08-29 Beecham Group Plc Compounds
WO1994006794A1 (en) * 1992-09-24 1994-03-31 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
WO1996010570A1 (en) * 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
ATE344249T1 (de) * 1999-07-19 2006-11-15 Merck Frosst Canada Ltd Pyrazinone, diese verbindungen enthaltende zusammenstellungen

Also Published As

Publication number Publication date
CN1397557A (zh) 2003-02-19
HUP0202282A2 (hu) 2003-03-28
CN1197863C (zh) 2005-04-20
SI1275647T1 (en) 2004-02-29
ZA200205596B (en) 2003-03-27
US6992085B2 (en) 2006-01-31
CA2394027C (fr) 2008-01-08
ES2210219T3 (es) 2004-07-01
PT1275647E (pt) 2004-03-31
HK1050682A1 (en) 2003-07-04
FR2827288B1 (fr) 2003-10-31
EP1275647A1 (fr) 2003-01-15
EA200200663A1 (ru) 2003-02-27
NO20023345L (no) 2003-01-13
NZ520120A (en) 2004-03-26
AU2002300094B2 (en) 2007-06-14
EP1275647B1 (fr) 2003-11-12
BR0202681A (pt) 2003-05-06
AR036166A1 (es) 2004-08-18
HUP0202282A3 (en) 2003-11-28
DE60200089D1 (de) 2003-12-18
TR200302001T4 (tr) 2004-01-21
US20030195216A1 (en) 2003-10-16
DK1275647T3 (da) 2004-03-15
JP3950018B2 (ja) 2007-07-25
DE60200089T2 (de) 2004-09-09
KR100485020B1 (ko) 2005-04-25
MXPA02006699A (es) 2005-08-16
NO322966B1 (no) 2006-12-18
EA005160B1 (ru) 2004-12-30
PL355034A1 (en) 2003-01-13
KR20030007159A (ko) 2003-01-23
NO20023345D0 (no) 2002-07-11
CA2394027A1 (fr) 2003-01-12
FR2827288A1 (fr) 2003-01-17
JP2003064081A (ja) 2003-03-05
ATE254124T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
BE2022C531I2 (enExample)
BE2022C502I2 (enExample)
BE2017C055I2 (enExample)
BE2017C032I2 (enExample)
BE2014C026I2 (enExample)
BE2007C047I2 (enExample)
AU2002307149A8 (enExample)
BE2011C034I2 (enExample)
HU0201646D0 (enExample)
BE2014C006I2 (enExample)
BRPI0209186B1 (enExample)
BE2017C050I2 (enExample)
BRPI0204884B1 (enExample)
CH1379220H1 (enExample)
BE2014C008I2 (enExample)
BE2016C021I2 (enExample)
JP2001326180A5 (enExample)
BRPI0101486B8 (enExample)
JP2002190409A5 (enExample)
JP2002118294A5 (enExample)
BRPI0210463A2 (enExample)
JP2001326364A5 (enExample)
AU2000280389A8 (enExample)
JP2002224843A5 (enExample)
JP2002217438A5 (enExample)

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished